Biovian brings full-range development and cGMP manufacturing offers to BIO-Europe 2017
Press Release | Biovian Ltd
NOVEMBER 01, 2017
Turku, Finland: – Specialist biopharmaceutical CMO Biovian will present the whole spectrum of its ‘gene to finished vial’ contract development and manufacturing (CDMO) offer at the upcoming BIO-Europe biotechnology partnering conference.
The Biovian team, led by CEO Dr. Knut Ringbom, will be on Booth 75a of the Exhibition Zone at the City Cube Berlin Conference Center.
Full-range cGMP services
The Biovian stand will present an upgraded portfolio of full range cGMP contract manufacturing services for mammalian, microbial and viral vector production, cell banking and storage, aseptic fill & finish, process development services and quality control.
Dr. Ringbom will be accompanied by Mr. Antti Nieminen, Biovian’s Director of Business Development and Projects.
Both will also be available for in-depth discussions with delegates, using the various networking and partnering platforms offered at the conference.
Recombinant protein expertise
The Biovian stand will also exhibit key features of its cGMP services, including microbial fermentation, mammalian cell culture, recombinant protein purification and formulation.
“We are delighted to be returning one more time to the BIO-Europe meeting, which provides us with a great platform to reach out to Drug Development companies across the continent,” said Antti Nieminen.
Once again it will give us great opportunities to discuss our very distinctive full-range cGMP offers for drug developers looking for CDMO services of very high quality and responsiveness, particularly when it comes to clinical trial material manufacturing,” Mr. Nieminen explained.
Biovian Ltd. is a one-stop-shop Contract Manufacturing Organization (CMO) specializing in full-process development and manufacture that extends ‘from gene to finished vial’.
Biovian offers Good Manufacturing Practice compliant (cGMP) services from its 2,700 square meter facilities in Turku, Finland, that are EMA and FDA certified for production of investigational and commercial products.
The CMO has more than a decade’s successful track record in pharmaceutical contract manufacturing ranging over a wide variety of different biopharmaceutical projects. Biovian GMP services include microbial fermentation, mammalian cell culture, viral vector production, protein purification, formulation, aseptic fill & finish, analytical quality control, stability studies and master cell banking. It also offers labeling, packaging, storage and QP release services.
Biovian also provides development services that cover cell line, process and analysis.
About BIO-Europe 2017
The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.
BIO-Europe 2017 is a three-day event opening November 6 at Berlin’s City Cube conference center.
BIO-Europe has formed the launchpad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.
This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.
Partnering at BIO-Europe 2017 is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.
More information at: https://ebdgroup.knect365.com/bioeurope/
Name: Antti Nieminen, Director, Business Development and Projects, Biovian Ltd.
Tel: +358 40 502 1332
Click on Biovian bringing latest ‘gene to finished vial’ offers to BIO-Europe for other information.
Click on Biovian to contact the company directly.
Click on From Gene to Finished Vial to watch latest Biovian video.